|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
70.538
(personal contribution)
|
||
|
£16.18
|
174.682
(personal contribution)
|
||
|
£16.18
|
190.188
(personal contribution)
|
||
|
£16.18
|
70.538(personal
contribution)
|
||
|
£16.18
|
174.669
(personal contribution)
|
||
|
£16.18
|
190.176
(personal contribution)
|
||
|
£16.18
|
70.538
(matching shares)
|
||
|
£16.18
|
174.682
(matching shares)
|
||
|
£16.18
|
190.188
(matching shares)
|
||
|
£16.18
|
70.538
(matching shares)
|
||
|
£16.18
|
174.669
(matching shares)
|
||
|
£16.18
|
190.176
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,741.582
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
51.658
(personal contribution)
|
||
|
£16.18
|
118.682
(personal contribution)
|
||
|
£16.18
|
99.029
(personal contribution)
|
||
|
£16.18
|
51.658
(personal contribution)
|
||
|
£16.18
|
99.017
(personal contribution)
|
||
|
£16.18
|
51.658
(matching shares)
|
||
|
£16.18
|
118.682
(matching shares)
|
||
|
£16.18
|
99.029
(matching shares)
|
||
|
£16.18
|
51.658
(matching shares)
|
||
|
£16.18
|
99.017
(matching contribution)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
840.088
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Debruyne
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
166.446
(personal contribution)
|
||
|
£16.18
|
166.433
(personal contribution)
|
||
|
£16.18
|
166.446
(matching shares)
|
||
|
£16.18
|
166.433
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
665.758
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
98.527
(personal contribution)
|
||
|
£16.18
|
230.682
(personal contribution)
|
||
|
£16.18
|
172.780
personal contribution)
|
||
|
£16.18
|
98.514
(personal contribution)
|
||
|
£16.18
|
230.669
(personal contribution)
|
||
|
£16.18
|
172.780
(personal contribution)
|
||
|
£16.18
|
98.527
(matching shares)
|
||
|
£16.18
|
230.682
(matching shares)
|
||
|
£16.18
|
172.780
(matching shares)
|
||
|
£16.18
|
98.514
(matching shares)
|
||
|
£16.18
|
230.669
(matching shares)
|
||
|
£16.18
|
172.780
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
2,007.904
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
36.169
(personal contribution)
|
||
|
£16.18
|
85.292
(personal contribution)
|
||
|
£16.18
|
62.593
(personal contribution)
|
||
|
£16.18
|
36.169
(personal contribution)
|
||
|
£16.18
|
85.292
(personal contribution)
|
||
|
£16.18
|
62.582
(personal contribution)
|
||
|
£16.18
|
36.169
(matching shares)
|
||
|
£16.18
|
85.292
(matching shares)
|
||
|
£16.18
|
62.593
(matching shares)
|
||
|
£16.18
|
36.169
(matching shares)
|
||
|
£16.18
|
85.292
(matching shares)
|
||
|
£16.18
|
62.582
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
736.194
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
170.501
(personal contribution)
|
||
|
£16.18
|
201.553
(personal contribution)
|
||
|
£16.18
|
173.006
personal contribution)
|
||
|
£16.18
|
201.553
(personal contribution)
|
||
|
£16.18
|
172.994
(personal contribution)
|
||
|
£16.18
|
170.501
(matching shares)
|
||
|
£16.18
|
201.553
(matching shares)
|
||
|
£16.18
|
173.006
(matching shares)
|
||
|
£16.18
|
201.553
(matching shares)
|
||
|
£16.18
|
172.994
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,839.214
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 July 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$42.50
|
70.929
(personal contribution)
|
||
|
$42.50
|
70.929
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
141.858
$42.50
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
57.960
(personal contribution)
|
||
|
£16.18
|
108.550
(personal contribution)
|
||
|
£16.18
|
78.775
(personal contribution)
|
||
|
£16.18
|
57.960
(personal contribution)
|
||
|
£16.18
|
108.550
(personal contribution)
|
||
|
£16.18
|
78.763
(personal contribution)
|
||
|
£16.18
|
57.960
(matching shares)
|
||
|
£16.18
|
108.550
(matching shares)
|
||
|
£16.18
|
78.775
(matching shares)
|
||
|
£16.18
|
57.960
(matching shares)
|
||
|
£16.18
|
108.550
(matching shares)
|
||
|
£16.18
|
78.763
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
981.116
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
78.015
(personal contribution)
|
||
|
£16.18
|
158.805
(personal contribution)
|
||
|
£16.18
|
118.568
(personal contribution)
|
||
|
£16.18
|
78.002
(personal contribution)
|
||
|
£16.18
|
158.805
(personal contribution)
|
||
|
£16.18
|
118.568
(personal contribution)
|
||
|
£16.18
|
78.015
(matching shares)
|
||
|
£16.18
|
158.805
(matching shares)
|
||
|
£16.18
|
118.568
(matching shares)
|
||
|
£16.18
|
78.002
(matching shares)
|
||
|
£16.18
|
158.805
(matching shares)
|
||
|
£16.18
|
118.568
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,421.526
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P C Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
52.988
(personal contribution)
|
||
|
£16.18
|
97.162
(personal contribution)
|
||
|
£16.18
|
74.644
(personal contribution)
|
||
|
£16.18
|
52.988
(matching shares)
|
||
|
£16.18
|
97.162
(matching shares)
|
||
|
£16.18
|
74.644
matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
449.588
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D E Troy
|
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 July 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$42.50
|
40.363
(personal contribution)
|
||
|
$42.50
|
90.880
(personal contribution)
|
||
|
$42.50
|
75.270
(personal contribution)
|
||
|
$42.50
|
40.363
(personal contribution)
|
||
|
$42.50
|
90.880
(personal contribution)
|
||
|
$42.50
|
75.258
(personal contribution)
|
||
|
$42.50
|
40.363
(matching shares)
|
||
|
$42.50
|
90.880
(matching shares)
|
||
|
$42.50
|
75.270
(matching shares)
|
||
|
$42.50
|
40.363
(matching shares)
|
||
|
$42.50
|
90.880
(matching shares)
|
||
|
$42.50
|
75.258
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
826.028
$42.50
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President,
R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 July 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.18
|
114.838
(personal contribution)
|
||
|
£16.18
|
186.805
(personal contribution)
|
||
|
£16.18
|
128.784
(personal contribution)
|
||
|
£16.18
|
114.838
(personal contribution)
|
||
|
£16.18
|
186.805
(personal contribution)
|
||
|
£16.18
|
128.784
(personal contribution)
|
||
|
£16.18
|
114.838
(matching shares)
|
||
|
£16.18
|
186.805
(matching shares)
|
||
|
£16.18
|
128.784
(matching shares)
|
||
|
£16.18
|
114.838
(matching shares)
|
||
|
£16.18
|
186.805
(matching shares)
|
||
|
£16.18
|
128.784
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,721.708
£16.18
|
|
|
e)
|
Date
of the transaction
|
2017-07-14
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
17, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|